Abstract
It has been postulated that the injectable solution formulation of remdesivir could be more nephrotoxic than the lyophilized powder since it contains twice as much sulfobutylether-β-cyclodextrin (SBECD). Therefore, we evaluated 1,000 hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) who received remdesivir lyophilized powder or solution. A logistic regression model accounting for baseline confounders identified that neither the use of the injectable solution (odds ratio [OR], 1.05; 95% confidence interval [CI], 0.49 to 2.29; P = 0.901) nor a creatinine clearance of <30 ml/min at the time of remdesivir initiation (OR, 1.39; 95% CI, 0.51 to 3.5; P = 0.499) was significantly associated with acute kidney injury. Regarding hepatoxicity, there was no significant difference in early discontinuation of remdesivir due to abnormal liver function tests between patients who received the lyophilized powder versus those who received solution (0.9% versus 2.3%, P = 0.09).
Keywords: SARS-CoV-2; lyophilized; remdesivir; renal failure; solution.
【저자키워드】 SARS-CoV-2, Remdesivir, lyophilized, renal failure, solution., 【초록키워드】 severe acute respiratory syndrome coronavirus 2, coronavirus, Remdesivir, Acute kidney injury, severe acute respiratory syndrome Coronavirus, Patient, renal failure, creatinine, Odds ratio, SBECD, creatinine clearance, cyclodextrin, Liver function test, acute respiratory syndrome, significant difference, solution, 95% CI, acute respiratory syndrome coronavirus, no significant difference, 95% confidence interval, logistic regression model, renal, clearance, nephrotoxic, confounder, sulfobutylether-β-cyclodextrin, significantly, evaluated, hospitalized patient, baseline, 【제목키워드】 Remdesivir, hepatic,